Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma

BACKGROUND: Omalizumab is approved for treating severe allergic asthma from age 6, but the definition of severe asthma including a systematic assessment to rule out difficult-to-treat asthma has changed since the drug was approved in 2003. METHODS: We conducted a systematic review and meta-analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Henriksen, Daniel P., Bodtger, Uffe, Sidenius, Kirsten, Maltbaek, Niels, Pedersen, Lars, Madsen, Hanne, Andersson, Ehm A., Norgaard, Ole, Madsen, Louise K., Chawes, Bo L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302157/
https://www.ncbi.nlm.nih.gov/pubmed/32565844
http://dx.doi.org/10.1186/s13223-020-00442-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302157/
https://www.ncbi.nlm.nih.gov/pubmed/32565844
http://dx.doi.org/10.1186/s13223-020-00442-0

Ejemplares similares